Korea Investment CORP Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Posted by Francis Steltz on Aug 25th, 2026

Korea Investment CORP purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 32,146 shares of the medical equipment provider’s stock, valued at approximately $2,767,000.

Other institutional investors have also made changes to their positions in the company. DV Equities LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at approximately $25,000. Tacita Capital Inc acquired a new position in Zimmer Biomet in the second quarter worth approximately $26,000. Monetary Solutions Ltd bought a new position in Zimmer Biomet during the fourth quarter valued at approximately $30,000. Gen Wealth Partners Inc bought a new position in Zimmer Biomet during the fourth quarter valued at approximately $31,000. Finally, Elevation Wealth Partners LLC lifted its stake in Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Trading Down 0.1%

NYSE:ZBH opened at $100.89 on Tuesday. The company’s 50 day moving average is $92.90 and its 200-day moving average is $91.14. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The firm has a market cap of $19.24 billion, a price-to-earnings ratio of 24.55, a P/E/G ratio of 2.75 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the prior year, the firm earned $2.07 EPS. Zimmer Biomet’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Analyst Ratings Changes

Several analysts have commented on the stock. Royal Bank Of Canada boosted their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research lowered shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 27th. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. Finally, BMO Capital Markets reissued a “market perform” rating and set a $96.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $104.42.

Check Out Our Latest Stock Report on ZBH

About Zimmer Biomet

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.